4.85
-0.15 (-2.91%)
| Previous Close | 4.99 |
| Volume | 1,306,626 |
| Price / Sales | 323.85 |
| Price / Book | 4.13 |
| 52 Weeks Range |
| Operating Margin (TTM) | -930.54% |
| Diluted EPS (TTM) | -0.340 |
| Quarterly Revenue Growth (YOY) | -32.50% |
| Total Debt/Equity (MRQ) | 111.93% |
| Current Ratio (MRQ) | 5.35 |
| Operating Cash Flow (TTM) | -83.45 M |
| Levered Free Cash Flow (TTM) | -52.28 M |
| Return on Assets (TTM) | -35.91% |
| Return on Equity (TTM) | -159.34% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Taysha Gene Therapies, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -1.67 |
|
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 12.11% |
| % Held by Institutions | 67.23% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Vestal Point Capital, Lp | 30 Jun 2026 | 19,415,000 |
| Siren, L.L.C. | 30 Jun 2026 | 9,846,579 |
| Octagon Capital Advisors Lp | 30 Jun 2026 | 9,693,244 |
| Polar Capital Holdings Plc | 30 Jun 2026 | 5,117,133 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |